Navigation Links
Chemokine Therapeutics Announces Preliminary Results of CTCE-9908,Phase Ib/II Clinical Trial in Late Stage Cancer Patients

s is believed to be critical in angiogenesis and in the metastasis (or spread) of cancer cells to distant locations in the body, where they form new tumors. Approximately 90% of cancer deaths are due to metastasis. We believe that CTCE-9908 interferes with the metastatic process of cancers by both preventing them to spread and blocking the blood supply to the cancer cells.

About Chemokine Therapeutics Corp.

Chemokine Therapeutics is a product-focused biotechnology company developing drugs in the field of chemokines. Chemokines are a class of signaling proteins which play a critical role in the growth, differentiation, and maturation of cells necessary for fighting infection as well as tissue repair and regeneration. Chemokines also have an important role in cancer metastasis and growth. Chemokine Therapeutics is a leader in research in the field of chemokines and has several products in various stages of development.

Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: Statements in this document regarding managements' future expectations, beliefs, goals, plans or prospects constitute forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "projects", and similar expressions are intended to identify forward-looking statements. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances, or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, those associated with the success of research and development p
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:12/24/2014)... PHILADELPHIA , Dec. 23, 2014 ... a medical device company focused on skin permeation, ... that Scott W. Hollander has been ... Mr. Hollander has more than 20 years of ... equipment industries, and most recently served as Vice ...
(Date:12/24/2014)... 23, 2014 ResMed (NYSE: RMD ) ... against Chinese medical device manufacturer BMC Medical Co., Ltd. ... BMC,s masks listed below infringe ResMed,s patents, and entered an ... in the United States : ... , Willow nasal pillows mask , iVolve full ...
(Date:12/24/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today announced validation ... Marketing Authorization Application (MAA) for sebelipase alfa for ... request for accelerated assessment, which has the potential ... The MAA, and the Biologics License ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... from Mayo ClinicROCHESTER, Minn., March 23 Here ... Edge, Mayo Clinic,s research magazine. You may cite ... you wish. Reprinting is allowed with proper attribution. ... editorial policies permit: Visit http://discoverysedge.mayo.edu for ...
... Since 1993, when the PLCO trial was started, we have ... have others. The initial report of the results of this ... published last week in the New England Journal of Medicine ... The studies offer conflicting evidence about the possibility of a ...
Cached Medicine Technology:Discovery's Edge Spring Issue - http://discoverysedge.mayo.edu 2A Joint Statement From America's Prostate Cancer Advocacy, Education, and Support Organizations 2A Joint Statement From America's Prostate Cancer Advocacy, Education, and Support Organizations 3
(Date:12/25/2014)... “Every three months the trends for ... evening dress will be one of the hottest styles in ... says. Today, the company releases 26 A-line sweetheart evening dresses, ... off. , “We are trying our best to help ... latest designs. Along with affordable prices, we provide discounted delivery ...
(Date:12/25/2014)... Los Angeles, CA (PRWEB) December 25, 2014 ... Blaise Dolcemaschio was created in honor of a true ... premiere at two film festivals including the 24 hours of ... Film Festival in Bangladesh. , Actress, screenwriter and ... and helped produce this film together with her husband, ...
(Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International founder ... an 8 year battle with breast cancer. , ... her home in Woodland Hills California after an 8 ... , As the founder and volunteer President of ... championed many of today's greatest breakthroughs in restoring and ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... children with complex chronic illnesses can receive effective, less expensive ... with easy access to a team of dedicated health care ... to become seriously ill and need either hospitalization or a ... an enhanced medical home clinic at the University of Texas ...
(Date:12/25/2014)... -- Among early stage breast cancer patients who undergo ... percent will eventually develop leukemia as a result of ... comes from a review of more than 20,000 breast ... suggests that the risk for developing treatment-related leukemia, though ... "The frequency of bone marrow cancers such as ...
Breaking Medicine News(10 mins):Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... CST-Arwin will represent the complete AC and DC line of axial ... more than 100 axial fans ranging in size from 25mm to ... ... -- NMB Technologies Corporation, a Minebea Group Company, and CST-Arwin, a ...
... WASHINGTON, DC, November 3, 2008 Parents are surprisingly ... visit to their child,s pediatrician, including those who have ... would look to their pediatrician for a referral, according ... the journal Pediatrics . , "This is a ...
... 3, 2008) Influenza vaccination rates for adolescents who suffer ... low, according to a recent study. , ... Pediatrics, was based at the Department of ... Harvard Pilgrim Health Care. , "Influenza vaccination has been ...
... RAMSEY, N.J., Nov. 3 Konica Minolta ... the industrial measurement of color,light and shape, ... Analysis Software.,This new software product used in ... accurate measurement of skin,color simultaneously with a ...
... two-pronged attack, a novel designer molecule fights malignant melanoma. It ... led by the University of Bonn. On the one hand, ... this way alerts the immune system. The body,s own defences ... the same time, the novel molecule also puts pressure on ...
... to Ask Voters ... of Health Care, TRENTON, N.J., Nov. 1 Calling themselves ... forces to ask the state,s public policy makers to put health ... level. The First Ladies,joined the newest members of the Partnership to ...
Cached Medicine News:Health News:NMB's Fans and Blowers to be Represented in Canada by CST-Arwin 2Health News:Parents comfortable with alcohol screening in pediatricians' offices 2Health News:Parents comfortable with alcohol screening in pediatricians' offices 3Health News:Flu vaccination rates lag for at-risk adolescents 2Health News:Konica Minolta Sensing Americas Announces the Launch of the CM-SA Skin Analysis Software 2Health News:Substance tackles skin cancer from 2 sides 2Health News:On Weekend Before the Election, New Jersey's First Ladies Speak Out for Healthcare 2Health News:On Weekend Before the Election, New Jersey's First Ladies Speak Out for Healthcare 3
Microalbumin Linearity Control...
Total IgE Control...
The K-ASSAY Lipid Controls are assayed controls produced from fresh human sera to monitor the accuracy and precision of quantitative lipid determinations of human sera specimens....
The K-ASSAY hs-CRP Control Set is intended to be used as a consistent test sample of known concentrations for monitoring the performance of hs-CRP (high sensitive C-Reactive Protein) immunoturbimetri...
Medicine Products: